GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bio-Rad Laboratories Inc (NYSE:BIO) » Definitions » EBIT

BIO (Bio-Rad Laboratories) EBIT : $-956 Mil (TTM As of Sep. 2024)


View and export this data going back to 1980. Start your Free Trial

What is Bio-Rad Laboratories EBIT?

Bio-Rad Laboratories's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2024 was $874 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was $-956 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Bio-Rad Laboratories's annualized ROC % for the quarter that ended in Sep. 2024 was 2.38%. Bio-Rad Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 205.06%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Bio-Rad Laboratories's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -10.41%.


Bio-Rad Laboratories EBIT Historical Data

The historical data trend for Bio-Rad Laboratories's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio-Rad Laboratories EBIT Chart

Bio-Rad Laboratories Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,284.50 4,939.87 5,450.61 -4,666.16 -800.67

Bio-Rad Laboratories Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 149.50 440.75 503.36 -2,774.02 873.79

Competitive Comparison of Bio-Rad Laboratories's EBIT

For the Medical Devices subindustry, Bio-Rad Laboratories's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bio-Rad Laboratories's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bio-Rad Laboratories's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Bio-Rad Laboratories's EV-to-EBIT falls into.



Bio-Rad Laboratories EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-956 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bio-Rad Laboratories  (NYSE:BIO) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Bio-Rad Laboratories's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

ROC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=257.864 * ( 1 - 24.19% )/( (7777.291 + 8669.18)/ 2 )
=195.4866984/8223.2355
=2.38 %

where

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=9688.446 - 295.049 - ( 1616.106 - max(0, 486.961 - 3056.254+1616.106))
=7777.291

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=10603.472 - 311.834 - ( 1622.458 - max(0, 497.943 - 3055.62+1622.458))
=8669.18

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Bio-Rad Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2024  Q: Sep. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=3495.176/( ( (715.24 + max(995.183, 0)) + (719.17 + max(979.315, 0)) )/ 2 )
=3495.176/( ( 1710.423 + 1698.485 )/ 2 )
=3495.176/1704.454
=205.06 %

where Working Capital is:

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(445.506 + 803.693 + 190.949) - (295.049 + 0 + 149.916)
=995.183

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(461.94 + 804.276 + 166.946) - (311.834 + 0 + 142.013)
=979.315

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Bio-Rad Laboratories's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2024 )
=-956.115/9184.444
=-10.41 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bio-Rad Laboratories EBIT Related Terms

Thank you for viewing the detailed overview of Bio-Rad Laboratories's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Bio-Rad Laboratories Business Description

Traded in Other Exchanges
Address
1000 Alfred Nobel Drive, Hercules, CA, USA, 94547
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (56% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (44% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (42% of 2023 sales), Europe (31%), Asia (31%), and other (6%). Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
Executives
Tania Devilliers officer: INT PRIN ACCTG OFC C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Sedat Evran officer: EVP, Global Supply Chain C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Corey Colleen officer: EVP, Global Human Resources 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Diane Dahowski officer: EVP, Global Supply Chain C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Schwartz Allison director C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Simon May officer: EVP, President, LSG C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Andrew J. Last officer: EVP, Chief Operating Officer 3420 CENTRAL EXPRESSWAY, SANTA CLARA CA 95051
Ajit Ramalingam officer: SVP, Chief Accounting Officer C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Ilan Daskal officer: EVP, Chief Financial Officer 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Timothy S Ernst officer: EVP, General Counsel & Sec 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Dara Wright officer: Executive Vice President C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Michael Crowley officer: EVP, GBL Commercial Operations 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Steven D Schwartz 10 percent owner 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Alice N Schwartz director, 10 percent owner
Norman D Schwartz director, 10 percent owner, officer: Chairman, President, and CEO 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547